A little research reveals that in addition to Organovo's IP asset, Wake Forrest institute for regenerative medicine holds a significant stake of bioprinting IP. The WF assets cover the use of cellular inputs as well as growth factors and substrates/scaffolds. To my knowledge, the University has done nothing to commercialize their assets yet, but given their long standing relationships with big pharma and rigorous clinical trial history, this could represent significant competition for ONVO in the future.
Just an FYI for the board.
cut and paste
Not inkjet printing
While Organovo's approach to bioprinting appears to be unique, there are currently others working on ways of printing new biological tissue, pointed out Stanford's Kraft.
He explained that Athony Atala, a researcher at Wake Forest University, has for some time been using reconfigured off-the-shelf inkjet printers for bioprinting (see video below). The idea there has been to print tissue that could be helpful to the thousands of soldiers who are injured in the wars in Iraq and Afghanistan.
But Organovo makes a point of differentiating its technology from what Atala and the Wake Forest team has achieved with inkjet printers by explaining that what it is doing is essentially rapid prototyping, and employs a process requiring no liquid and no nozzle.
"Organovo creates [the] bio-ink of discrete cellular aggregates, each made up of many cells," the company's white paper said. "These are used as a building block, as the bioprinter places these cell aggregates within high precision into a predetermined pattern."
Not everyone who isn't flooding the board with all positive news/vibes is an unwanted short. I think xanderarena makes a valid point and I very much appreciate him/her doing so. The board would be absolutely useless if everyone was just pumping all the time.
TNGN market cap $1.7m. Gone from $50 to $0.75 per share in 3 years. Does not seem to be a going concern. The last 3-days volume and price have increased on no news ... maybe due to attention from ONVO. Unless there is a patent conflict (unlikely) it should be of no concern.
I wouldn't worry too much about TGN, it looks like they are done. The bladder implant (based of growing patient's cells on decellularized bladders) seems not to be working...or at least the info about the clinical study is gone. Now they launched a clinical study on the neo-kidney augment, but they don't explain how the technology actually works.